Mass General Brigham Ventures

Portfolio Companies 2026 for Mass General Brigham Ventures: investors, rounds, and co-investor patterns from StartupFundraising.com research, updated for 2026.

Mass General Brigham Ventures accounts for 11 tracked companies with verified cap-table data, 11 of which disclose round sizes totalling $1.5B. The median disclosed raise is $133M, and the largest is Spur Therapeutics at $274M, ahead of Amolyt Pharma ($210M) and Abcuro ($200M).

The names that recur most often on these portfolio cap tables are Mass General Brigham Ventures (11 companies), RA Capital Management (3 companies), Sofinnova Partners (2 companies), Sanofi Ventures (2 companies), Eurofarma Ventures (2 companies), Bristol Myers Squibb (2 companies). By latest disclosed round, the market skews Series A (5), Series C (3), Series B (2).

Best funded Mass General Brigham Ventures companies

  1. Spur Therapeutics — $274M
  2. Amolyt Pharma — $210M (latest: Series C)
  3. Abcuro — $200M (latest: Series C)
  4. ROME Therapeutics — $199M (latest: Series B)
  5. Mediar Therapeutics — $181M (latest: Series A)
  6. SwanBio Therapeutics — $133M (latest: Series B)
  7. Photys Therapeutics — $75M (latest: Series A)
  8. Tuesday Health — $60M (latest: Series A)
  9. Claris Biotherapeutics — $57M (latest: Series A)
  10. InStride Health — $56M (latest: Series C)
  11. Rippl Care — $55M (latest: Series A)

Mass General Brigham Ventures — related firms and companies (54)

Mass General Brigham Ventures alternatives · All research reports